Company Overview of Biozone Pharmaceuticals, Inc.
As of January 2, 2014, Biozone Pharmaceuticals, Inc. was acquired by Cocrystal Discovery, Inc., in a reverse merger transaction. Biozone Pharmaceuticals, Inc., through its subsidiaries, engages in developing and manufacturing over the counter (OTC) drug products, and cosmetic and beauty products on behalf of third parties in the United States and internationally. Its OTC products include hair conditioners and shampoos for treatment of eczema and psoriasis; external analgesics; skin protectants; anti-fungal products; topical anesthetics; nasal sprays; wound care products; acne products; cough and cold products; anti-itch products; and skin lightening products. The company’s cosmetic and beaut...
550 Sylvan Avenue
Englewood Cliffs, NJ 07632
Key Executives for Biozone Pharmaceuticals, Inc.
Biozone Pharmaceuticals, Inc. does not have any Key Executives recorded.
Biozone Pharmaceuticals, Inc. Key Developments
Biozone Pharmaceuticals, Inc. Announces Management Appointments
Jan 3 14
Biozone Pharmaceuticals, Inc. announced that it has finalized its planned merger with Cocrystal Discovery, Inc. Concurrent with the closing of the merger, Dr. Gary Wilcox has been appointed Chief Executive Officer and Chairman of the Board. Dr. Wilcox previously served on the Board of Directors and was Executive Vice President of Operations at Icos Corporation from 1993 through its sale to Eli Lilly for $2.3 billion in 2007. At Icos he led the team developing Cialis, which now has annual sales over $2 billion. Additionally, Dr. Roger Kornberg, has been appointed Chief Scientist and a Director of the combined entities. Joining Dr. Wilcox and Dr. Fornberg on the Board of Directors is Dr. Phillip Frost, Dr. Sam Lee, Steven Rubin and Dr. Jane Hsiao. Dr. Frost is currently the Chairman and CEO of Opko Health, Inc, and the Chairman of the Board of Teva Pharmaceuticals. Dr. Hsiao is Vice Chairman and Chief Technical Officer of Opko Health, Inc. Additionally, the following individuals were appointed as executive officers of Biozone: Gary Wilcox as Secretary; Sam Lee as President; Gerald McGuire as Chief Financial Officer and Treasurer. Mr. McGuire has served as Cocrystal's interim Chief Financial Officer since April 2012. Elliot Maza, Roberto Prego-Novo and Brian Keller, directors of Biozone, resigned effective at the time of the closing of the Merger. Elliot Maza, Brian Keller and Christian Oertle, the pre-Merger Biozone executive officers, resigned from all of their positions with Biozone.
Biozone Pharmaceuticals, Inc. announced delayed ammended 10-Q filing
Nov 13 13
On 11/13/2013, Biozone Pharmaceuticals, Inc. announced that they will be unable to file their ammended 10-Q by the deadline required by the SEC.
Biozone Pharmaceuticals, Inc. announced delayed 10-Q filing
Nov 12 13
On 11/12/2013, Biozone Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Similar Private Companies By Industry
Recent Private Companies Transactions